On Friday shares of Westmoreland Coal Co. (NASDAQ:WLB) closed at $28.74. Company’s sales growth for last 5 years was 20.30% and EPS growth for next 5 years is recorded as 10.00%. Westmoreland Coal Company (NASDAQ:WLB) announced results of the first quarter ended March 31, 2015. Revenues for the quarter were $371.5 million versus $180.2 million in the same quarter in 2014. Adjusted EBITDA for the first quarter of 2015 was $56.0 million, while Adjusted EBITDA for the first quarter of 2014 was $28.9 million.
Synthetic Biologics Inc. (NYSEMKT:SYN) in last trading activity moved up 0.43% to close at $2.33. Company weekly performance is -1.27% while its quarterly performance stands at 52.29%. Synthetic Biologics Inc. (NYSEMKT:SYN) is -26.61% away from its 52 week high. Synthetic Biologics, Inc. (NYSEMKT:SYN), announced that preclinical data from its novel SYN-005 program for the treatment of Pertussis were presented in two posters at ECCMID 2015 (European Congress of Clinical Microbiology and Infectious Diseases), on April 25, 2015, in Copenhagen, Denmark.
On last trading day Stemline Therapeutics, Inc. (NASDAQ:STML) decreased -2.47% to close at $16.58. Its volatility for the week is 3.12% while volatility for the month is 4.21%. STML’s EPS growth for past 5 years was -16.90%. Stemline Therapeutics, Inc. (NASDAQ:STML) monthly performance is 8.65%. Research analysts at HC Wainright started coverage on shares of Stemline Therapeutics (NASDAQ:STML) in a report released on Monday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock.
Celgene Corporation (NASDAQ:CELG) has 0.20% insider ownership while its institutional ownership stands at 83.30%. In last trading activity company’s stock closed at $118.71. Celgene Corp. (NASDAQ:CELG) said that it agreed to acquire Quanticel Pharmaceuticals Inc., a privately held biotechnology company focused on cancer drug discovery. As per the agreement terms, Celgene will acquire Quanticel for an upfront payment of $100 million in cash. Up to an additional $385 million in contingent payments may be achieved upon research, development, and regulatory advances related to Quanticel’s research and development platform.
On last trading day Synta Pharmaceuticals Corp. (NASDAQ:SNTA) decreased -9.43% to close at $2.69. Its volatility for the week is 6.43% while volatility for the month is 6.37%. SNTA’s EPS growth for past 5 years was -18.90%. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) monthly performance is 13.50%. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced that Chen Schor, Executive Vice President, Chief Operating Officer, has been named President, Chief Executive Officer and a Director of the Company, effective May 7, 2015. Mr. Schor replaces Anne Whitaker, who is stepping down from her roles at Synta to pursue a professional opportunity at a large multinational pharmaceutical company.